Zydus Launches World's First Nivolumab Biosimilar in India, Slashes Cancer Costs

• Zydus Lifesciences launched Tishtha™, the world's first biosimilar of cancer immunotherapy drug Nivolumab, in India on January 22.
• Tishtha™ will treat multiple cancers and is priced at nearly one-fourth the cost of the reference drug, significantly reducing patient burden.
• Available in 100 mg (₹28,950) and 40 mg (₹13,950) dosages, allowing oncologists to optimize dosing and minimize drug wastage.
• The Made-in-India biosimilar aims to benefit over five lakh patients by improving affordability and access to immuno-oncology therapies.
• This launch strengthens Zydus's presence in advanced biologics and immuno-oncology, aligning with its strategy to expand high-quality biosimilar access.

Why It Matters: Zydus's Tishtha™ launch makes advanced cancer immunotherapy affordable and accessible in India, benefiting many patients.